Supplement | HBS Case Collection | November 2007

Teva Pharmaceutical Industries, Ltd.

by Tarun Khanna and Krishna G. Palepu

Abstract

How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's largest and first multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has undergone significant change over the last 20 years. Examines Teva's strategies to defend itself against both low-cost competitors from India and other emerging markets as well as Big Pharma companies, which are adopting increasingly aggressive tactics in generics.

Keywords: Multinational Firms and Management; Emerging Markets; Rank and Position; Competitive Strategy; Pharmaceutical Industry; Israel; India;

Citation:

Khanna, Tarun, and Krishna G. Palepu. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Video Supplement 708-806, November 2007.